The top pharmaceutical companies are trying every approach they can imagine to find the weakness in COVID-19’s armor. Pharma companies that were arch enemies are working together. Drugs that are approved for other diseases are being tested as treatments. The front runner is Gilead Sciences (GILD) with its lead candidate remdesivir. Gilead expects initial trial results in April. On speculative evidence from a phone call cited by STAT report that remdesivir patients were responding to treatment the stock shot up 9.73%, or $10.5 billion, on hopes of a decent trial report. Soon to